0P5I fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Mauna Kea Technologies SA engages in the design, development, and sale of optical biopsy devices and tools to visualize and detect abnormalities in the gastro-intestinal and pulmonary tracts primarily in cancer patients. Its product, Cellvizio, a probe-based Confocal Laser Endomicroscopy system, provides physicians and researchers high resolution cellular views of tissue inside the body. Mauna Kea Technologies was founded by Sacha Loiseau and Benjamin Abrat in May 2000 and is headquartered in Paris, France.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
0P5I does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company